Xilio Therapeutics Inc
XLOBuild a strategy around XLO
Xilio Therapeutics Inc AI Insights
Informational only. Not investment advice.Snapshot
- Negative equity (-8.1M) with liabilities (141.8M) exceeding assets (133.7M) - technically insolvent balance sheet requiring capital raise or partnership.[Total Equity]
- Cash burn of -17.6M FCF TTM against 103.8M cash = ~6 quarters runway. Revenue 31.8M covers only 42% of 75.6M operating expenses.[Free Cash Flow TTM]
- R&D spend 46.8M TTM is 147% of revenue - classic pre-commercial biotech profile with binary clinical outcomes ahead.[Research and Development TTM]
Watch Triggers
- Cash and Equivalents: Falls below 60M — Would signal <4 quarters runway, forcing dilutive raise at distressed terms
- Total Revenue TTM: Exceeds 50M or new partnership announced — Would extend runway and validate pipeline commercial potential
- Research and Development TTM: Drops >20% without revenue offset — Could signal pipeline abandonment or pivot - changes thesis entirely
Bull Case
Trading below cash value (EV -0.6M) with 103.8M cash means pipeline optionality is essentially free. Any clinical success reprices equity dramatically.
Revenue grew 7.4% YoY to 31.8M (above industry median 22.1M) suggesting partnership/licensing traction that could accelerate with pipeline progress.
Bear Case
Negative equity (-8.1M) and -137.6% operating margin signal structural insolvency. Dilution from inevitable capital raise could exceed 50% at current prices.
Burn rate (-17.6M FCF) consumes 17% of cash quarterly. Pipeline failure would leave minimal liquidation value given 7.8M PP&E and negative book.
Bull vs Bear Balance
AI-generated sentiment analysis based on fundamental metrics and market conditions.
Leverage XLO's top insights and create a custom strategy based on them in seconds. Our AI editor does it all — in one click.
Forward Thesis
Capital raise or strategic partnership required within 12-18 months to fund operations
- Cash runway ~6 quarters at current burn
- Negative equity limits debt capacity
- R&D-heavy model needs sustained funding
Binary outcome: pipeline success drives 3-5x upside, failure risks near-total loss
- Market cap 95.9M vs 46.8M annual R&D
- EV negative at -0.6M signals distress pricing
- Revenue 7.4% growth insufficient to reach profitability
Valuation Context
Caveats
Public Strategies Rankings
See how Xilio Therapeutics Inc ranks across different investment strategies.
Leverage XLO's top insights and create a custom strategy in seconds. Our AI editor does it all — in one click.
XLO Fundamentals
| Metric | Value | YoY Growth | Industry Percentile |
|---|---|---|---|
$34.93M | — | ||
$-95.65M | — | ||
0.00 | — | ||
$43.77M | +589.9% | — | |
$-58.66 | — | ||
-95.9% | +844.3% | — | |
-80.1% | +838.0% | — | |
$-5.51M | — | ||
-133% | +81.5% | — | |
Beta 5Y (Monthly) | unknown | — |
XLO Dividend History
XLO Stock Splits
XLO SEC Filings
| Filing Date | Report Date | Report Type | Filing Link |
|---|---|---|---|
03/23/26 | 12/31/25 | Unknown | |
11/13/25 | 09/30/25 | 10-Q | |
08/14/25 | 06/30/25 | 10-Q | |
05/08/25 | 03/31/25 | 10-Q | |
03/11/25 | 12/31/24 | Unknown | |
11/07/24 | 09/30/24 | 10-Q | |
08/08/24 | 06/30/24 | 10-Q | |
05/14/24 | 03/31/24 | 10-Q | |
04/01/24 | 12/31/23 | 10-K | |
11/09/23 | 09/30/23 | 10-Q | |
08/14/23 | 06/30/23 | 10-Q | |
05/09/23 | 03/31/23 | 10-Q | |
03/02/23 | 12/31/22 | 10-K | |
11/09/22 | 09/30/22 | 10-Q | |
08/09/22 | 06/30/22 | 10-Q | |
05/12/22 | 03/31/22 | 10-Q | |
03/01/22 | 12/31/21 | 10-K | |
12/02/21 | 09/30/21 | 10-Q | |
10/22/21 | 06/30/21 | 424B4 | |
05/12/22 | 03/31/21 | 10-Q | |
10/22/21 | 12/31/20 | 424B4 | |
12/02/21 | 09/30/20 | 10-Q |